Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients

Alexis Cuffel a, Sarah Maylin b, Helene Le Buanec c, Constance Delaugerre b,d, Marine Minier b, David Bergerat c, Marine Merandet c, Charles Cassius e, Régis Peffault de Latour f, Jérôme Le Goff b,g, Gérard Socié f,g, Sophie Caillat-Zucman a,g, Marie Robin f, Aliénor Xhaard f,*

⇑ Corresponding author at: Service d'hématologie-greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, 1 avenue Claude Vellefaux, 75475 Paris, Cedex 10, France.
E-mail address: alienor.xhaard@aphp.fr (A. Xhaard).

https://doi.org/10.1016/j.vaccine.2022.07.006
0264-410X/© 2022 Elsevier Ltd. All rights reserved.

A R T I C L E  I N F O

Article history:
Received 21 February 2022
Received in revised form 3 July 2022
Accepted 5 July 2022
Available online 11 July 2022

A B S T R A C T

Previous studies reporting the response to SARS-CoV-2 mRNA vaccination in alloHSCT recipients used serological and/or cellular assays, but no study has evaluated vaccine-induced neutralizing antibodies. We prospectively studied 28 alloHSCT recipients who received two BNT162b2 doses. Two patients groups were defined according to time from alloHSCT and immunosuppressive treatment, and had different baseline immunologic status. Study end-point was the evaluation of humoral and cellular responses one month after the second vaccine.

All patients seroconverted. Anti-S IgG levels and neutralizing antibodies percentages were not significantly different between both groups. Using IFNγ ELISpot assay, five patients showed a strong increase, without correlation with the humoral response. Using flow cytometry lymphocyte proliferation assay, 14 patients exhibited responding T cells, without difference between both groups or correlation with anti-S IgG levels. A few low serological responders had a detectable CD4+ T cell proliferative response. This finding should be confirmed in a larger cohort.

1. Introduction

SARS-CoV-2 induced coronavirus disease 2019 (COVID-19) is associated with a mortality rate around 25% among allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients [1,2]. In the general population, BNT162b2 mRNA vaccine confers a 90–95% protection against symptomatic COVID-19 [3,4]. However, the recent emergence of the B.1.1.529 (omicron) variant challenged the efficacy of vaccination, especially before the injection of a booster dose [5–8]. Previous studies of influenza and pneumococcus vaccines showed a weaker antibody response in alloHSCT recipients compared with the general population [9]. Previous studies [10–14] reporting responses to SARS-CoV-2 mRNA vaccination in alloHSCT recipients used serological and/or cellular assays, but no study has evaluated vaccine-induced neutralizing antibodies (nAb) in this population.

2. Material and methods

Twenty-eight adult alloHSCT recipients transplanted for a hematological malignancy, who received two doses of the BNT162b2 vaccine from six months post-transplantation, were prospectively included between January and March 2021. All patients had baseline serological and immunological evaluation before vaccination (T0). The study end-point was the evaluation of humoral and cellular responses to the SARS-CoV-2 vaccine at a median of 30 days (range: 7–56) after the second dose (T2). All patients gave their consent for data collection before transplantation.

Testing for SARS-CoV-2 IgG was performed on the Abbott Alinity system, with qualitative detection of IgG antibodies against nucleocapsid protein (N) and quantitative detection of IgG against the RBD of the S1 subunit of the spike protein. Test
results ≥ 50 arbitrary units (AU)/mL were reported as reactive and interpreted as positive for anti-S IgG. This assay has an analytical measuring interval of 21–40 000 AU/mL (up to 80 000 AU/mL with on-board 1:2 dilution). Non-responders were defined as anti-S IgG levels < 50 AU/mL, and low-responders as anti-S IgG > 50 but < 4 160 AU/mL, as this threshold corresponds to a 0.95 probability of virus neutralization in in vitro neutralization tests [15,16].

A SARS-CoV-2 surrogate neutralization assay, based on antibody-mediated blockade of ACE-2-spike protein interaction, was used (ichromax Covid-19 nAB, Boditech, South Korea). A fluorescence inhibition above 30% (meaning 30% interference with the SARS-CoV-2 spike RBD protein and ACE-2 receptor by neutralizing antibodies) is considered positive. This semi-quantitative assay correlates with a neutralizing SARS-CoV-2 Ab ELISA assay (Boditech Package insert).

Cellular responses were evaluated using a flow cytometry-based lymphocyte proliferation assay: Cell Trace Violet (CTV)-stained PBMCs (2x10⁶/mL) were stimulated for seven days at 37 °C in the absence (medium alone) or presence of the SARS-CoV-2 spike protein (2.5 μg/mL, R&D systems), as reported [12]. Proliferation was quantified by flow cytometry according to CTV dilution in T cells, following surface staining with anti-CD3, -CD4 and -CD8 antibodies (BD Biosciences) and live/dead exclusion. Acquisitions were performed on a BD FACSCount iITM flow cytometer and analyses performed using BD FACSDiva™ software version 7. Results were considered positive if > 0.5% of cells proliferated in presence of the spike protein (after subtracting proliferation in medium alone). Cellular responses were also evaluated using IFNγ enzyme-linked immunoassay (ELISpot) following overnight stimulation with 15-mer peptides spanning the SARS-CoV-2 spike protein (2 mg/mL, Miltenyi Biotec). Spots were counted using an automated ELISpot Reader System (Autoimmun Diagnostika GmbH). In the absence of a control cohort, ELISpot results were evaluated as a fold increase (FI), normalizing the difference between T2 and T0 on the T0 value (FI = (T2-T0)/T0).

Categorical variables were compared using the two-sided chi-square test. Comparisons between groups of patients were performed using the Mann-Whitney test, and a comparison between timepoints using the Wilcoxon matched-pairs test. Correlations were performed using the Spearman test. P < 0.05 was determined significant. All statistical tests were performed with GraphPad Prism software version 8.4.0.

3. Results

Patient characteristics, immunological baseline evaluation and post-vaccination humoral response are detailed in Table 1. Two groups of patients were defined according to the time from alloHSCT and immunosuppressive treatment (IST) at vaccination. Group 1 comprised 14 patients within two years from alloHSCT or still receiving IST at vaccination (n = 10, 61%). Group 2 included 14 patients beyond two years from alloHSCT, without IST. No patient had a clinical history of previous COVID-19 and the T0 serological assay was anti-N and anti-S IgG negative for all patients. Before vaccination, group 1 patients had significantly lower total peripheral blood lymphocytes, total and naive CD4 + T cells, and gamma globulins.

No patient had a clinical history of COVID-19 after vaccination and anti-N IgG were still negative at T2. No patient was a non-responder to the vaccine, but nine were low responders (seven patients from group 1 and two from group 2, p = 0.043) (Table 1). Median anti-S IgG level in the total cohort was 11,498 UA/mL (range: 236–80 000), with a trend towards lower levels in group 1 (p = 0.08) (Fig. 1A).

Fig. 1. A. Median titers of anti-S IgG in both groups. B. Comparison of neutralizing antibodies in both groups. C. Correlation between anti-S IgG level and neutralization. D. Flow cytometry CD3 + T cells proliferation assay.
cantly different between both groups. The median percentage of nAb was 86.8% for the entire population. Five patients had nAb titers below 30% (three in group 1 and two in group 2). In patients above 30%, median percentage of nAb was 92.4% (range: 40.7–99.4%), without a significant difference between groups (Fig. 1B). Anti-S IgG levels and nAb proportions were strongly correlated (R = 0.94, p < 0.0001) (Fig. 1C).

IFNγ T cell responses to spike peptide pools were available in 21 patients (10 in group 1 and 11 in group 2). Ten patients (48%) showed no increase in cellular response at T2 (FI < 1) and only five (24%) showed a strong increase (FI > 10). There was no correlation between the intensity of the cellular response and the anti-S IgG level or percentage of nAb.

T cell proliferative response to the spike protein was evaluated by flow cytometry in 21 patients (nine in group 1 and 12 in group 2). Fourteen patients (50%) exhibited spike-specific responding T cells at T2 (median 7.75%, range: 0.6–22.9%), without difference between both groups (Fig. 1D). The proportion of proliferating cells was higher among CD4+ T cells than CD8+ T cells. Correlation between the CD4+ T cell proliferative response and anti-S IgG levels was barely significant (p = 0.06).

We did not expect a 100% seroconversion rate after SARS-CoV-2 vaccination in our cohort, as previous reports in alloHSCT recipients showed post-vaccine serological responses of 69% to 83%. This high seroconversion rate could be related to the rather long interval from alloHSCT to vaccination in our cohort (median 5.6 years). In previous publications, Redjoul et al. report a 78% rate of seroconversion among 88 alloHSCT recipients vaccinated a median of six months after alloHSCT, while Le Bourgeois et al. report an 83% seroconversion rate among 97 alloHSCT recipients vaccinated a median of 645 days after alloHSCT. In these two publications, although the median time from alloHSCT to vaccination was quite different (six months, versus 1.7 years), the seroconversion rates were around 80%. This suggests that time from alloHSCT to vaccination by itself is not the most important factor for post-vaccination seroconversion, but has to be taken into account, alongside other factors, such as immunological recovery and immunosuppressive treatments, among others. Our results also highlight the fact that patients with acute and/or chronic GVHD requiring immunosuppressive treatment should still be offered anti-SARS-CoV-2 vaccination, as it may lead to a significant antibody and/or cellular response.

| Table 1 | Patient characteristics. |
|---------|--------------------------|
| Patients (n = ) | Total | Group 1 | Group 2 | P value |
| 28 | 14 | 14 |
| Median age at vaccination (range) (years) | 51.5 (35–70) | 56 (38–68) | 58 (35–70) | 0.83 |
| Male sex | 17 (61) | 10 (71) | 7 (50) |
| Hematological disease | | | | |
| Acute myeloblastic leukemia | 16 (56) | 6 (43) | 10 (71) | 0.47 |
| Non-Hodgkin lymphoma | 5 (18) | 3 (21) | 2 (14) |
| Myelodysplastic syndrome | 4 (14) | 3 (21) | 1 (7) |
| Myeloproliferative neoplasm | 3 (11) | 2 (14) | 1 (7) |
| Other* | 0 | 0 | 0 |
| Median age at transplantation (range) (years) | 51.5 (29–65) | 51 (35–65) | 51.5 (29–65) | 0.33 |
| Myeloblastic conditioning | 9 (32) | 5 (36) | 5 (36) |
| Donor type | | | | |
| Matched related | 12 (43) | 7 (50) | 5 (36) | 0.24 |
| Mismatched unrelated | 5 (18) | 1 (7) | 4 (28) |
| Haplo-identical | 2 (7) | 2 (14) | 0 |
| Stem cell source | | | | |
| Peripheral blood | 26 (93) | 14 (100) | 12 (86) | 0.34 |
| Bone marrow | 1 (3.5) | 0 | 1 (7) |
| Cord blood | 1 (3.5) | 0 | 1 (7) |
| Acute or Chronic Graft-versus-Host-Disease | | | | |
| 11 (79) | 0 | <0.0001 |
| Immunological status before first vaccine dose | | | | |
| Peripheral blood lymphocytes (G/L) | 1.78 | 548 | 585 (0.7–1.65) | 2.16 (1.46–3.6) | 0.05 |
| CD4+ (mmm3) | 50 | 333 (79–1,212) | 667 (334–1,459) | 0.01 |
| Naive CD4+ (mmm3) | 93 (20Pt) | 28 (8–187) | 179 (25–375) | 0.04 |
| CD8+ (mmm3) | 673 (11Pt) | 629 (45–2645) | 673 (270–1,915) | 0.6 |
| CD19+ (mmm3) | 353 | 270 (40–975) | 428 (205–1,656) | 0.09 |
| CD56+ (mmm3) | 243 | 234 (42–892) | 313 (116–730) | 0.35 |
| Gamma globulins (g/L) | 8.2 (27Pt) | 6.4 (2.4–15.5) | 10.7 (7.1–13.3) | 0.008 |
| Median time from alloHSCT to first vaccine injection (years) (range) | 5.6 (0.6–16.8) | 2 (0.6–14.1) | 8.6 (3.1–16.8) | 0.004 |
| Serological response after two vaccine injections | | | | |
| Anti-S IgG > 50 AU/mL | 28 (100%) | 14 (100%) | 14 (100%) |
| Anti-S IgG > 4 160 AU/mL | 19 (68%) | 7 (50%) | 12 (86%) | 0.043 |
| Median levels of anti-S IgG levels (UA/mL) | 11 498 | 4 680 | 13 774 | 0.08 |
| Median levels of anti-S IgG levels (if > 4,160 AU/mL) | 18 985 | 21 671 | 21 067 | 0.9 |
| Neutralizing antibodies > 30% | (5 805–80 000) | (5 805–49 721) | (7 514–80 000) | >0.99 |
| Median titer of neutralizing antibodies | 23 (32%) | 11 (78.6%) | 12 (85.7%) | 0.11 |
| Median titer of neutralizing antibodies (if > 30%) | 92.4% (38.1–99.4) | 80.2% (38.1–98.7) | 94.2% (42.3–99.4) | 0.08 |

* : Acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, n = 1 each.
Anti-S IgG levels and nAb percentages were not significantly different between both groups, although their baseline immunological status was clearly different. The strong correlation between anti-S IgG levels and neutralization is particularly interesting with the emergence of SARS-CoV-2 variants, which question the threshold for positivity of antibody response. Although cellular responses were less frequently detected than serologic ones, we observed that a few patients considered as low serological responders had a detectable CD4 + T cell proliferative response. In the context of the emergence of SARS-CoV-2 variants associated with a lower efficacy of vaccine-induced nAb, the evidence of a CD4 + T cell proliferative response to the spike protein is important to maintain an immune response against SARS-CoV-2.

In view of these results, we studied six additional non-responder patients, who received a third vaccine dose a median of 56 days (range: 33–78) after the second vaccine injection. Median time from alloHSCT to first dose was 3.3 years (range: 0.4–10.9), and three patients were less than two years from alloHSCT or still receiving IST. A median of 38 days (range: 27–51) after the third dose, anti-S IgG were < 50 AU/mL in one patient and > 4 160 AU/mL in two others, leaving three low responders. The nAb were < 10% in non-responders and low responders, while a significant nAb response was observed in the two responders. The flow cytometry lymphocyte proliferation assay showed a specific CD4 + T cell response in three patients (two responders and one non-responder). Thus, a third dose of SARS-CoV-2 vaccine may induce a protective antibody response in a subset of alloHSCT patients, as previously reported [12].

4. Conclusions

Although based on a small cohort of alloHSCT recipients, our data show a high rate of serological response, including a high proportion of neutralizing antibodies, after BNT162b2 SARS-CoV-2 vaccination. We show that a cellular response can be detected in the absence of serological response. A similar observation has already been described in CAR-T cell recipients with complete B cell aplasia [10]. That a cellular response can be detected in the absence of a humoral response, particularly in the context of the lack of B cell recovery, should be further documented in a larger cohort, comprising patients receiving three vaccine doses.

CRediT authorship contribution statement

Alienor Xhaard: designed the study, recruited patients, collected data, analyzed the data, wrote the manuscript.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors wish to thank Elodie Lesy for her assistance.

References

[1] Xhaard A, Xhaard C, D’Aveni M, Salvador H, Chabi M-L, Berceanu A, et al. Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM-TC) multicentre cohort study. Br J Haematol 2021;192(5).
[2] Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation: results from an EBMT and GEMH multicenter prospective survey. Leukemia 2021;35(10):2885–94.
[3] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603–15.
[4] Dajani N, Barda N, Kepten E, Miron O, Perchuk S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021;384(15):1412–23.
[5] Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med 2022;386(7):698–700.
[6] Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med 2022;386(5):494–6.
[7] Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 2022;185(3):457–466.e4.
[8] Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 2022;185(3):447–456.e11.
[9] Kennedy LB, Li Z, Savani BN, Ljungman P. Measuring Immune Response to Commonly Used Vaccinations in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2017;23(10):1614–21.
[10] Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med 2022;386(7):698–700.
[11] Redjoul R, Le Bouter A, Parinet V, Fourati S, Maury S. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. The Lancet 2021;398(10297):298–9.
[12] Redjoul R, Le Bouter A, Parinet V, Fourati S, Maury S. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. The Lancet Haematology 2021;8(10):e681–3.
[13] Le Bourgeois A, Coste-Burel M, Guillaume T, Peterlin P, Garnier A, Béné MC, et al. Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open 2021;4(9):e2126344.
[14] Harrington P, Dooves KJ, Saha C, Saunders J, Child F, Dillon R, et al. Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients. Cancer Cell 2021;39(12):1654.
[15] Ebinger JE, Fert-Robier J, Printsev I, Wu M, Sun N, Prostko JC, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med 2021;27(6):981–4.
[16] Malard F, Gaugler B, Gozlank J, Bouquet I, Fofana D, Siblany L, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J 2021;11(8).